Literature DB >> 11810272

The molecular basis of familial hypercholesterolemia in The Netherlands.

S W Fouchier1, J C Defesche, M W Umans-Eckenhausen, J P Kastelein.   

Abstract

Mutations in the low-density lipoprotein (LDL) receptor gene are responsible for familial hypercholesterolemia (FH). At present, more than 600 mutations in this gene are known to underlie FH. However, the array of mutations varies considerably in different populations. Therefore, the delineation of essentially all LDL-receptor gene mutations in a population is a prerequisite for the implementation of nation-wide genetic testing for FH. In the Netherlands, mutation analysis by denaturing gradient gel electrophoresis and sequencing in 1641 clinically diagnosed FH patients resulted in the characterization of 159 different LDL-receptor gene defects. The nine most common mutations were responsible for 66.5% of our FH index cases. Of these, four mutations occurred with relatively high frequencies in specific parts of the Netherlands. The remaining mutations were only encountered in single FH patients, comprising 22.2% of the patient cohort analyzed. Subsequent genetic testing of relatives of the index cases within the national FH screening program resulted in the identification of 5,531 FH patients in total. The analysis for LDL-receptor mutations is a continuing effort to update the LDL-receptor mutation catalogue. Subsequently, with the newly generated index cases, the screening program can be extended and continued to identify and treat FH patients as early as possible and reduce cardiovascular morbidity and mortality in these patients at high risk.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11810272     DOI: 10.1007/s00439-001-0628-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  36 in total

1.  Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia.

Authors:  Heleen E Wiersma; Albert Wiegman; Richard P Koopmans; Henk D Bakker; John J P Kastelein; Chris J van Boxtel
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

2.  Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families.

Authors:  Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik
Journal:  Hum Genet       Date:  2010-04-11       Impact factor: 4.132

3.  Identification of roles for H264, H306, H439, and H635 in acid-dependent lipoprotein release by the LDL receptor.

Authors:  Hongyun Dong; Zhenze Zhao; Drake G LeBrun; Peter Michaely
Journal:  J Lipid Res       Date:  2016-11-28       Impact factor: 5.922

4.  Identification of a recurrent insertion mutation in the LDLR gene in a Pakistani family with autosomal dominant hypercholesterolemia.

Authors:  Muhammad Ajmal; Waqas Ahmed; Ahmed Sadeque; Syeda Hafiza Benish Ali; Syed Habib Bokhari; Nuzhat Ahmed; Raheel Qamar
Journal:  Mol Biol Rep       Date:  2010-03-10       Impact factor: 2.316

Review 5.  Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease.

Authors:  George Yuan; Jian Wang; Robert A Hegele
Journal:  CMAJ       Date:  2006-04-11       Impact factor: 8.262

6.  A novel pathogenic variant of the LDLR gene in the Asian population and its clinical correlation with familial hypercholesterolemia.

Authors:  J K Chahil; S H Lye; P G Bagali; L Alex
Journal:  Mol Biol Rep       Date:  2012-04-28       Impact factor: 2.316

7.  Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene.

Authors:  Mariame El Messal; Karima Aït Chihab; Rachid Chater; Joan Carles Vallvé; Faïza Bennis; Aïcha Hafidi; Josep Ribalta; Mathilde Varret; Mohammed Loutfi; Jean Pierre Rabès; Anass Kettani; Catherine Boileau; Luis Masana; Ahmed Adlouni
Journal:  J Hum Genet       Date:  2003-03-18       Impact factor: 3.172

8.  [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation].

Authors:  José M A Lobos Bejarano; Miguel Angel Royo-Bordonada; Carlos Brotons; Luís Alvarez-Sala; Pedro Armario; Antonio Maiques; Dídac Mauricio; Susana Sans; Fernando Villar; Angel Lizcano; Antonio Gil-Núñez; Fernando de Alvaro; Pedro Conthe; Emilio Luengo; Alfonso Del Río; Olga Cortés; Ana de Santiago; Miguel A Vargas; Mercedes Martínez; Vicenta Lizarbe
Journal:  Aten Primaria       Date:  2009-07-15       Impact factor: 1.137

9.  Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia.

Authors:  Jeroen B van der Net; Daniëlla M Oosterveer; Jorie Versmissen; Joep C Defesche; Mojgan Yazdanpanah; Bradley E Aouizerat; Ewout W Steyerberg; Mary J Malloy; Clive R Pullinger; John J P Kastelein; John P Kane; Eric J G Sijbrands
Journal:  Eur Heart J       Date:  2008-07-03       Impact factor: 29.983

10.  Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.

Authors:  Markey C McNutt; Hyock Joo Kwon; Chiyuan Chen; Justin R Chen; Jay D Horton; Thomas A Lagace
Journal:  J Biol Chem       Date:  2009-02-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.